Clinical Trial Update: Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of Bintrafusp Alfa in HMGA2-expressing triple-negative breast cancer was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Bintrafusp alfa (bintrafusp alfa)

Snippet

Sponsor: EMD Serono Research & Development Institute, Inc. | Conditions: Triple Negative Breast Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2023-04-10